Online inquiry

IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8914MR)

This product GTTS-WQ8914MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Chronic idiopathic urticaria research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8914MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8059MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ14588MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ3007MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ14096MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ3246MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ5163MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ726MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ7840MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW